Literature DB >> 24326167

Understanding the economic burden of nonsevere nocturnal hypoglycemic events: impact on work productivity, disease management, and resource utilization.

Meryl Brod1, Michael Wolden, Torsten Christensen, Donald M Bushnell.   

Abstract

OBJECTIVE: Nonsevere hypoglycemic events are common and may occur in one-third of persons with diabetes as often as several times a week. This study's objective was to examine the economic burden of nonsevere nocturnal hypoglycemic events (NSNHEs).
METHODS: A 20-minute Web-based survey, with items derived from the literature, expert input, and patient interviews, assessing the impact of NSNHEs was administered in nine countries to 18 years and older patients with self-reported diabetes having an NSNHE in the past month.
RESULTS: A total of 20,212 persons were screened, with 2,108 respondents meeting criteria and included in the analysis sample. The cost of lost work productivity per NSNHE was estimated to be between $10.21 (Germany) and $28.13 (the United Kingdom), representing 3.3 to 7.5 hours of lost work time per event. A reduction in work productivity (presenteeism) was also reported. Compared with respondents' usual blood sugar monitoring practice, on average, 3.6 ± 6.6 extra tests were conducted in the week following the event at a cost of approximately $87.1 per year. Additional costs were also incurred for doctor visits as well as medical care required because of falls or injuries incurred during the NSNHE for an annual cost of $2,111.3 per person per year. When taking into consideration the multiple impacts of NSNHEs for the total sample and the frequency that these events occur, the resulting total annual economic burden was $288,000 or $127 per person per event.
CONCLUSIONS: NSNHEs have serious consequences for patients. Greater attention to treatments that reduce NSNHEs can have a major impact on reducing the economic burden of diabetes.
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  economic burden; nocturnal hypoglycemia; resource utilization; work productivity

Mesh:

Year:  2013        PMID: 24326167     DOI: 10.1016/j.jval.2013.09.002

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  23 in total

1.  Assessing the impact of non-severe hypoglycemic events and treatment in adults: development of the Treatment-Related Impact Measure-Non-severe Hypoglycemic Events (TRIM-HYPO).

Authors:  Meryl Brod; Lise Højbjerre; Donald M Bushnell; Charlotte Thim Hansen
Journal:  Qual Life Res       Date:  2015-06-21       Impact factor: 4.147

2.  Self-reported Hypoglycaemic Events in 2 430 Patients with Insulin-treated Diabetes in the German Sub-population of the HAT Study.

Authors:  Werner Kern; Andreas Holstein; Christian Moenninghoff; Joachim Kienhöfer; Matthias Riedl; Bernhard Kulzer
Journal:  Exp Clin Endocrinol Diabetes       Date:  2017-07-27       Impact factor: 2.949

Review 3.  The benefits, limitations, and cost-effectiveness of advanced technologies in the management of patients with diabetes mellitus.

Authors:  Robert A Vigersky
Journal:  J Diabetes Sci Technol       Date:  2015-03

Review 4.  Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes.

Authors:  David Rodbard
Journal:  Diabetes Technol Ther       Date:  2017-06       Impact factor: 6.118

Review 5.  Minimising hypoglycaemia in the real world: the challenge of insulin.

Authors:  Chantal Mathieu
Journal:  Diabetologia       Date:  2021-01-16       Impact factor: 10.122

6.  Modern insulins, old paradigms and pragmatism: choosing wisely when deciding how to treat type 1 diabetes.

Authors:  Beatriz D Schaan; Rafael Selbach Scheffel
Journal:  Diabetol Metab Syndr       Date:  2015-04-22       Impact factor: 3.320

Review 7.  Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives.

Authors:  Bastiaan E de Galan
Journal:  Patient Prefer Adherence       Date:  2016-10-17       Impact factor: 2.711

8.  Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study.

Authors:  K Khunti; S Alsifri; R Aronson; M Cigrovski Berković; C Enters-Weijnen; T Forsén; G Galstyan; P Geelhoed-Duijvestijn; M Goldfracht; H Gydesen; R Kapur; N Lalic; B Ludvik; E Moberg; U Pedersen-Bjergaard; A Ramachandran
Journal:  Diabetes Obes Metab       Date:  2016-06-20       Impact factor: 6.577

9.  Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.

Authors:  Bruno Detournay; Serge Halimi; Julien Robert; Céline Deschaseaux; Sylvie Dejager
Journal:  Vasc Health Risk Manag       Date:  2015-07-17

Review 10.  Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis.

Authors:  Nick Freemantle; Engels Chou; Christian Frois; Daisy Zhuo; Walter Lehmacher; Aleksandra Vlajnic; Hongwei Wang; Hsing-Wen Chung; Quanwu Zhang; Eric Wu; Charles Gerrits
Journal:  BMJ Open       Date:  2016-02-15       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.